You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
HUCBC modulation of Alzheimer's-like pathology and behavioral changes
SBC: SANERON CCEL THERAPEUTICS, INC. Topic: NIADESCRIPTION (provided by applicant): In the past years, we have shown that human umbilical cord blood cells (HUCBC, U-CORD- CELL ) provide cognitive recovery in animal models of neurodegenerative disease. Infusion of HUCBC resulted in reduced infarct volume as well as in rescue of behavioral benefits in an animal model of stroke. We further showed that HUCBC infusion proved to be beneficial in ani ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Targeting glioblastoma stem-like cells with custom-designed viral vectors
SBC: Lacerta Therapeutics, Inc. Topic: 102Glioblastoma (GBM) is the most lethal form of adult brain cancers with a median survival of andlt;15 months despite aggressive standard chemoradiation. GBM are formed by GBM stem-like cells (GSCs) - a major contributor to tumor recurrence and a natural focus for therapeutic development. There are two main reasons responsible for treatment failure: 1) high intra- and inter-tumor cellular and molecu ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
HLS- Cyclic CAR peptide: a targeted therapy for pulmonary hypertension
SBC: VASCULAR BIOSCIENCES, INC. Topic: NHLBIPUBLIC ABSTRACT This projectin response to announcement HLSdescribes a development program for CARSKNKDCCARa synthetic cyclic peptide that selectively targets diseased pulmonary vascular endothelium and enhances the therapeutic effect of vasodilator therapiesfor the treatment of pulmonary hypertensionPHPH is a disorder of elevated pulmonary vascular resistance characterized by progressive thickeni ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
A Home Exercise Program (DVD) for Women with Infants and Young Children
SBC: KLEIN BUENDEL, INC. Topic: NIDADESCRIPTION (provided by applicant): Becoming a mother is a significant transition in a woman's life. This transition can precipitate major changes in health behaviors, like physical activity. Once a woman has a child she is much less likely to participate in regular, moderate to vigorous physical activity compared to women without children. Thus, new mothers are at risk for future weight gain and ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Testing a male oral contraceptive targeting Eppin
SBC: EPPIN PHARMA INC Topic: NICHDThe global contraceptives market was valued at $billion inand is expected to grow at a CAGR offromtoto reach an estimated value of $billion inThe contraceptive market consists of short term methods such as condoms and oral contraceptionlong term methods including implants and IUDsand permanent methods such as tubal ligations and vasectomiesEppin Pharmaandapos s product has a unique set of characte ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Acute-infarct selective cardiac MRI contrast agent
SBC: ELGAVISH PARAMAGNETICS, INC. Topic: NHLBIDESCRIPTION provided by applicant The overall goal of this project is to demonstrate the ability of our acute myocardial infarct selective paramagnetic contrast agent Gadolinium ABE DTTA to differentiate between acute and chronic infarcts in a reliable manner using contrast enhanced magnetic resonance imaging ceMRI In our Phase I data we have shown that Gd ABE DTTA exclusively highlight ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Developing a Small Peptide to Control Autoimmune Inflammation In Type 1 Diabetes
SBC: Op-T-Mune, Inc Topic: NIAIDType 1 Diabetes (T1D) affects an ever growing population. While this disease typically has been associated with juveniles, the disease in adult populations is rapidly increasing. The defining clinical component is insulin loss, which occurs because of sustained inflammation in the islets. At present there is no means to prevent or reverse insulin loss. A major inflammatory pathway in T1D that cont ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
LC-MS System to Determine the Molecular Mass of Synthesized Heparan and Chondroitin Sulfate Oligosaccharides
SBC: GLYCAN THERAPEUTICS CORPORATION Topic: 300This fast-track STTR application proposes to synthesize structurally defined heparan sulfate and chondroitin sulfate oligosaccharides for biological research. Glycan Therapeutics is a biotech company specialized in synthesizing sulfated carbohydrates using innovative enzyme-based methods. This proposal is focused on the synthesis of large authentic oligosaccharides in the size range of 10-mers to ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Testing and Commercialization of a Superior Device to Maintain Perioperative Normothermia In Anesthetized Patients
SBC: Mercury Biomed LLC Topic: 300Project SummaryAbstractThis proposal presents Phase II of Mercury Biomedandapos s plan for commercializing the new and innovative WarmSmart technology to more effectively keep surgical patients normothermicWarmSmart embodies several breakthrough concepts in bioheat transfer to manage core temperatureWe are building a costcompetitive patient warming technology that will be superior to existing tech ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Personalized Neural Stem Cell Therapy for Cancer
SBC: Falcon Therapeutics, Inc. Topic: NCATSPROJECT SUMMARY Glioblastoma (GBM) is an intractable cancer with an average survival time of 12 to 15 months. Treatment options are limited by the infiltration of tumor cells into healthy tissue and the difficulty of delivering effective chemotherapeutics across the blood brain barrier, but engineered neural stem cells (NSCs) hold great promise as GBM therapies because they selectively migrate to ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health